Cutting edge therapies are blurring the delineation of treatment between the medical and pharmacy fields. This is especially true in genetic medicine: pharmacogenetics/genomics, gene therapy, immuno-oncology, personalized medicine and predictive medicine. Determining the effectiveness and risks associated with these novel, and sometimes custom, treatments requires an understanding of the molecular biology underlying the condition and therapy. TGCA specializes in clearly, concisely and accurately defining these complex concepts. We help navigate the health risk decision tree, allowing you to enhance your patient-focused care, and identify and fill gaps in the provision of care to achieve optimal outcomes for all stakeholders in the care continuum.